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MaBACKGROUND Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused
by sarcomere protein (SP) gene mutations is current standard of care, but there are few data on long-term outcomes in
mutation carriers without HCM.
OBJECTIVES The aim of this study was to determine the incidence of new HCM diagnosis in SP mutation carriers.
METHODS This was a retrospective analysis of adult and pediatric SP mutation carriers identified during family
screening who did not fulfill diagnostic criteria for HCM at first evaluation.
RESULTS The authors evaluated 285 individuals from 156 families (median age 14.2 years [interquartile range: 6.8 to
31.6 years], 141 [49.5%] male individuals); 145 (50.9%) underwent cardiac magnetic resonance (CMR). Frequency of
causal genes was as follows: MYBPC3 n ¼ 123 (43.2%), MYH7 n ¼ 69 (24.2%), TNNI3 n ¼ 39 (13.7%), TNNT2 n ¼ 34
(11.9%), TPM1 n ¼ 9 (3.2%), MYL2 n ¼ 6 (2.1%), ACTC1 n ¼ 1 (0.4%), multiple mutations n ¼ 4 (1.4%). Median follow-up
was 8.0 years (interquartile range: 4.0 to 13.3 years) and 86 (30.2%) patients developed HCM; 16 of 50 (32.0%) fulfilled
diagnostic criteria on CMR but not echocardiography. Estimated HCM penetrance at 15 years of follow-up was 46% (95%
confidence interval [CI]: 38% to 54%). In a multivariable model adjusted for age and stratified for CMR, independent
predictors of HCM development were male sex (hazard ratio [HR]: 2.91; 95% CI: 1.82 to 4.65) and abnormal electro-
cardiogram (ECG) (HR: 4.02; 95% CI: 2.51 to 6.44); TNNI3 variants had the lowest risk (HR: 0.19; 95% CI: 0.07 to 0.55,
compared to MYBPC3).
CONCLUSIONS Following a first negative screening, approximately 50% of SP mutation carriers develop HCM
over 15 years of follow-up. Male sex and an abnormal ECG are associated with a higher risk of developing
HCM. Regular CMR should be considered in long-term screening. (J Am Coll Cardiol 2020;76:550–9)
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LV = left ventricular
P/LP = pathogenic/likely
pathogenic
SCD = sudden cardiac death
SP = sarcomere protein
J A C C V O L . 7 6 , N O . 5 , 2 0 2 0 Lorenzini et al.
A U G U S T 4 , 2 0 2 0 : 5 5 0 – 9 Penetrance in Sarcomere Mutation Carriers
551P rovision of genetic testing to the relatives ofpatients with hypertrophic cardiomyopathy(HCM) caused by pathogenic/likely pathogenic
(P/LP) variants in sarcomere protein (SP) genes is
standard of care in clinical practice guidelines (1).
Adoption of this recommendation has led to the iden-
tification of a growing number of individuals that
carry SP gene P/LP variants in the absence of an overt
cardiomyopathy on cardiac imaging who are offered
lifelong follow-up. The evidence to support this strat-
egy is, however, relatively weak (2–8), as most studies
are limited by small cohort size, restriction to chil-
dren (2,3), and the influence of founder SP gene vari-
ants (7,8). Ongoing screening of healthy SP P/LP
variant carriers also poses a potentially unsustainable
burden on health care providers and relatives alike.
The primary aim of this study was to determine the
incidence of a new HCM diagnosis in relatives
with SP P/LP variants and to evaluate predictors of
phenotype development. The secondary aim was to
assess the incidence of major cardiovascular events
in relatives carrying SP P/LP variants.SEE PAGE 560METHODS
This was a retrospective analysis of consecutive
adult and pediatric SP P/LP variant carriers identified
during family screening and who did not fulfill
diagnostic criteria for HCM (1) at first clinical evalu-
ation. All were evaluated between 1988 and October
2018 at the Inherited Cardiovascular Diseases units
at The Heart Hospital, St Bartholomew’s Hospital,
and Great Ormond Street Hospital in London.
All underwent standard electrocardiography (ECG)
and 2-dimensional echocardiography at 1 to 3 yearly
intervals and cardiac magnetic resonance (CMR)
imaging at physician’s discretion as previously
described (9). The study conforms to the declaration
of Helsinki (10) and the retrospective data collection
was approved by the local ethics committee (refer-
ence 19/WS/0100).
GENETICS. All SP variants were reviewed and clas-
sified in January 2020 according to the American
College of Medical Genetics and Genomics criteria
(11). Only individuals with pathogenic or likely path-
ogenic variants in MYBPC3, MYH7, TNNI3, TNNT2,
MYL2, MYL3, TPM1, or ACTC1 were included in the
study. Family members underwent genetic testing for
SP variants identified in index cases using automated
DNA sequencing methods on an ABI3130 genetic
analyzer and BigDye Terminator v3.1 cycle
sequencing chemistry and standard protocols
(Applied Biosystems, Foster City, California).STUDY ENDPOINTS AND DEFINITIONS. The
primary endpoint was a new diagnosis of
HCM defined as left ventricular (LV) hyper-
trophy not explained solely by loading con-
ditions (1). Specifically:
 Adults: LV wall thickness $13 mm on
echocardiogram or CMR.
 Children: LV wall thickness more than 2
standard deviations (SDs) greater than the
predicted mean (z-score >2).
The time of onset of the primary endpoint
was defined as the earliest time a subject
fulfilled the diagnostic criteria for HCM. Data
were included up to the last available follow-
up at the time the database was closed (June 30,
2019); subjects who did not reach the primary
endpoint were censored at the time of their last
evaluation. In subjects who died with no clinical
diagnosis of HCM, the primary endpoint was adjudi-
cated based on the postmortem results or censored at
the time of their last evaluation in absence of a
postmortem.
The incidence of major cardiovascular events (all-
cause mortality, cardiac transplantation, aborted
sudden cardiac death [SCD], and appropriate
implantable cardioverter-defibrillator [ICD] shock)
was determined from the time of diagnosis of HCM to
the most recent follow-up. SCD was defined as wit-
nessed SCD with or without documented ventricular
fibrillation or death within 1 h of new symptoms or
nocturnal deaths with no antecedent history of
worsening symptoms (12). Successful resuscitation
from ventricular fibrillation or ventricular tachycardia
during follow-up and appropriate ICD shock therapy
were considered equivalent to SCD (13–16).
ECGs were reviewed blindly by 4 cardiologists (ML
and LRL in adults, JPK and GN in children); disagree-
ments were resolved by a third blinded reviewer
(MMA); when original tracings were unavailable, data
were obtained from the ECG description and inter-
pretation in the medical record at the time of clinical
evaluation. ECG classification was based on the pres-
ence or absence of abnormalities associated with HCM.
Specifically: LV hypertrophy by Sokolow-Lyon criteria
(SV1þRV5/6 >35 mV) in pediatric cases, and by
Sokolow-Lyon or Cornell criteria (RaVLþSV3 >28 mV
inmen and>22 mV in women) in adults; and abnormal
Q waves, and repolarization abnormalities.
Pediatric patients were defined as having been
age <18 years at first evaluation. For the purposes of
this analysis, patients were considered to have un-
dergone CMR when they were scanned <2 years
before the end of follow-up. Hypertension was
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cord and ongoing treatment with at least 1 antihy-
pertensive agent.
STATISTICAL ANALYSIS. Statistical analyses were
performed using IBM SPSS Statistics version 24.0
(IBM Corp., Armonk, New York) and STATA version
12. For descriptive statistics, variables are expressed
as median (interquartile range [IQR]) or counts and
percentages, as appropriate. The frequency of cate-
gorical variables was compared with chi-square or
Fisher exact test as appropriate and continuous var-
iables were compared using Student’s t-test (2-tailed,
unpaired samples), Mann-Whitney U test, or Kruskal-
Wallis analysis of variance. HCM penetrance was
estimated using the Kaplan-Meier method with
follow-up as time variable, abnormal ECG was
analyzed as a time-varying covariate; groups were
compared using the log-rank test. The 5 age cate-
gories used for Kaplan-Meier analysis were estab-
lished based on clinically significant cutoffs. Hazard
ratios were obtained by univariable and multivariable
analyses using a Cox proportional hazards model. The
proportional hazards assumption was verified using
Schoenfeld residuals (17). The final Cox multivariable
model was stratified by CMR because it violated the
proportional hazards assumption as a covariate.
RESULTS
A total of 583 P/LP variant carriers from 307 families
were evaluated; 267 (45.8%) were diagnosed with
HCM at first evaluation and were excluded from the
study. Supplemental Figure 1 shows the distribution
by age of those diagnosed with HCM at first evalua-
tion. A further 31 subjects underwent a single
screening visit and were also excluded. The final
study cohort therefore consisted of 285 individuals
from 156 families who did not fulfill diagnostic
criteria for HCM at first evaluation; 141 (49.5%) were
male and median age at first evaluation was 14.2 years
(IQR: 6.8 to 31.6 years); 167 subjects (58.6%) were
aged <18 years (including some who have been pre-
viously reported [9]).
The frequency of causal genes was as follows:
MYBPC3 123 individuals (43.2%), MYH7 69 individuals
(24.2%), TNNI3 39 individuals (13.7%), TNNT2 34 in-
dividuals (11.9%), TPM1 9 individuals (3.2%), MYL2 6
individuals (2.1%), ACTC1 a single individual (0.4%),
and MYL3 none. In addition, 4 individuals (1.4%) car-
ried multiple P/LP variants (MYBPC3 and TNNI3 in 3,
MYH7 and TNNT2 in 1). Supplemental Table 1 reports
the variant details for the study cohort. By family, the
frequency of causal genes was as follows: MYBPC3 71families (45.5%), MYH7 44 families (28.2%), TNNI3 17
families (10.9%), TNNT2 15 families (9.6%), TPM1 3
families (1.9%), MYL2 3 families (1.9%), ACTC1 one
family (0.6%), MYL3 none; 2 families (1.3%) carried
multiple P/LP variants.
After a median follow-up of 8.0 years (IQR: 4.0 to
13.3 years), 86 patients (30.2%) reached the primary
study endpoint; 41 (14.4%) had an abnormal ECG but
did not fulfill diagnostic criteria and 158 (55.4%) had a
normal ECG and echocardiogram (Figure 1). The 3
groups differed by genotype, sex, and age, with a
higher male prevalence among those who developed
overt HCM, and younger age in individuals with only
an abnormal ECG compared with those with a normal
phenotype and those with overt HCM (Table 1).
Supplemental Figure 2 shows the phenotype at the
end of follow-up according to age.
Overall, HCM penetrance at 15 years follow-up was
46% (95% confidence interval [CI]: 38% to 54%) and
was greater in male than in female individuals (58%;
95% CI: 47% to 70% vs. 33%; 95% CI: 24% to 46%) at 15
years follow-up (Central Illustration). Table 2 reports
the characteristics of the study cohort by sex.
At 15 years follow-up, estimated HCM penetrance
by causal gene was as follows: MYBPC3 43% (95% CI:
32% to 57%), MYH7 66% (95% CI: 47% to 83%), TNNI3
17% (95% CI: 7% to 39%), TNNT2 50% (95% CI: 30% to
74%), TPM1 42% (95% CI: 11% to 92%), and multiple
variants 63% (95% CI: 19% to 99%) (Figure 2A).
Supplemental Table 2 reports the characteristics of
the study cohort by age at first evaluation; penetrance
was similar in the pediatric and adult subgroups
(Figure 2C).
At the time of diagnosis of HCM, 60 (72.3%) of 83
patients had an abnormal ECG (ECG data not available
for 3 patients). Of these, 45 (54.2%) of 83 had an
abnormal ECG before fulfilling the diagnostic criteria
and this was first documented a median 4.4 years
(range: 2.0 to 7.5 years) prior (range 0.2 to 13.1 years)
(Figure 1). An abnormal ECG was a strong risk factor
for a subsequent diagnosis of HCM (Figure 2B).
Overall, 145 subjects (50.9%) underwent a CMR
with no clear difference between those who devel-
oped HCM and those who did not (Table 1). Among
those diagnosed with HCM who underwent CMR, 16
(32.0%) of 50 fulfilled criteria on CMR but not echo-
cardiography; 50% of these individuals (n ¼ 8) had a
normal ECG at the time of HCM diagnosis (Figure 3).
A multivariable model stratified by evaluation with
CMR demonstrated the independent predictive value
of male sex and an abnormal ECG before the end of
follow-up. Compared with patients with MYBPC3,
individuals with TNNI3 variants had a lower








(n ¼ 86) p Value
Genotype
MYBPC3 76 (48.1) 9 (22.0) 38 (44.2) <0.001
MYH7 28 (17.7) 16 (39.0) 25 (29.1)
MYL2 4 (2.5) 0 (0.0) 2 (2.3)
TNNI3 32 (20.3) 3 (7.3) 4 (4.7)
TNNT2 11 (7.0) 12 (29.3) 11 (12.8)
TPM1 5 (3.2) 1 (2.4) 3 (3.5)
ACTC1 0 (0.0) 0 (0.0) 1 (1.2)
Multiple mutations 2 (1.3) 0 (0.0) 2 (2.3)
Age, yrs 16.9 (7.5–32.6) 6.9 (3.5–12.6) 16.0 (9.2–35.0) <0.001
Male 72 (39.3) 24 (51.1) 55 (61.8) 0.002
Follow-up duration, yrs 9.1 (3.3–13.7) 6.9 (3.5–10.5) 7.7 (5.4–11.6) 0.276
Hypertension 5 (3.2) 1 (2.4) 7 (8.1) 0.206
CMR 75 (47.5) 20 (48.8) 50 (58.1) 0.270
Values are n (%) or median (interquartile range). p value is for overall comparison.
CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; HCM ¼ hypertrophic cardiomyopathy (i.e.,
fulfills diagnostic criteria).


















































37 patients (45.1%)3.3 yrs (1.9-5.5)*
More than one-half of the subjects with an abnormal electrocardiogram (ECG) went on to develop overt hypertrophic cardiomyopathy (HCM).
Those with an abnormal ECG but no overt HCM at the end of follow-up were younger, suggesting they will probably go on to develop overt
HCM, although follow-up time from the first abnormal ECG was not clearly different between the 2 groups (*p ¼ 0.794). Ages reported are
median (interquartile range). †At first abnormal ECG. ‡At first screening visit.
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553penetrance of HCM. Older age at first evaluation was
also associated with an increased risk (Table 3).
CLINICAL OUTCOMES. No cases of death or aborted
SCD were recorded in individuals who did not fulfill
HCM criteria. Following the diagnosis of HCM, over a
median follow-up of 4.1 years (2.3 to 9.0 years) (total
528.4 person-years), 2 patients died suddenly (1 with
an ICD in situ that was not downloaded at the time of
postmortem), 1 experienced aborted SCD (ventricular
fibrillation) and was successfully resuscitated, and 2
patients received appropriate ICD shocks. One patient
died following superior vena cava rupture during
ICD extraction. The overall event rate was 1.1%
per year.
DISCUSSION
Based on the analysis of this large cohort of pediatric
and adult SP gene P/LP variant carriers, disease
penetrance in relatives without disease at first eval-
uation is higher than previously described (2–8). SCDs
(or equivalent) were recorded exclusively in patients
with an established diagnosis of HCM.
Several small studies have prospectively evaluated
disease penetrance in SP P/LP variant carriers (2–8),
reporting estimates up to 18%. However, most reports
were limited by small cohort size, and some lackedgeneralizability due to inclusion of a high percentage
of subjects with founder MYBPC3 variants (7,8). The
greater diversity in affected genes in our study might
explain the higher disease penetrance observed. The
younger age at baseline evaluation compared with
the other published series (4,7) may also be relevant,




(n ¼ 144) p Value
Genotype
MYBPC3 62 (44.0) 61 (42.4) 0.581
MYH7 30 (21.3) 39 (27.1)
MYL2 3 (2.1) 3 (2.1)
TNNI3 17 (12.1) 22 (15.3)
TNNT2 21 (14.9) 13 (9.0)
TPM1 5 (3.5) 4 (2.8)
ACTC1 0 (0.0) 1 (0.7)
Multiple mutations 3 (2.1) 1 (0.7)
Age, yrs 12.6 (6.8–28.5) 16.2 (6.7–35.6) 0.257
Follow-up duration, yrs 7.7 (3.3–12.3) 9.2 (4.6–13.6) 0.027
Abnormal ECG during follow-up 44 (31.2) 38 (26.4) 0.369
Hypertension 5 (3.5) 8 (5.6) 0.416
CMR 71 (50.4) 74 (51.4) 0.861
Diagnostic CMR, nondiagnostic echo 10 (7.1) 6 (4.2) 0.283
Values are n (%) or median (interquartile range). p value is for comparison.
Abbreviations as in Table 1.
CENTRAL ILLUSTRATION Kaplan-Meier Estimates of Penetrance of Hypertrophic Cardiomyopathy in the






















285 adult and pediatric carriers of
pathogenic/likely
pathogenic sarcomere
protein variants with no 
hypertrophic cardiomyopathy (HCM)
Penetrance of HCM at  15-year follow-up:
46% (95% CI: 38%-54%)
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Male sex and abnormal electrocardiogram are risk factors for penetrance of hypertrophic cardiomyopathy (HCM) in carriers of pathogenic/likely path-
ogenic variants in sarcomere genes, while TNNI3 variants are protective.
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554as older age at inclusion in a prospective study
probably biases toward individuals less likely to
develop HCM.
A male prevalence of approximately 60% is a con-
stant finding in large HCM cohorts and, based on our
findings, this could be explained by a higher pene-
trance of SP gene P/LP variants in male individuals.
After adjusting for baseline differences (including
genotype), imaging technique, and age, we found the
risk of developing HCM to be 3 times higher in male
individuals. This remains unexplained, as does the
higher mortality that has been observed in female
individuals in large HCM cohorts in spite of this male
predominance (18–20).
An abnormal ECG was strongly associated with the
subsequent development of HCM (Figure 2B) and was
independent of genotype and sex. This confirms the
important role of the ECG as a screening tool as well
as the need for long-term surveillance in individuals
with an abnormal ECG. However, a normal ECG did































































































































Penetrance is lowest in subjects with TNNI3 variants, compared to MYBPC3, MYH7, and TNNT2 (A), was similar in adult and pediatric subjects (C), and an abnormal ECG
was a strong predictor of subsequently developing overt HCM (B). Abbreviations as in Figure 1.
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FIGURE 3 Utility of CMR for Screening
Localized left ventricular hypertrophy involving the basal antero-septum and anterior wall in a 23-year-old man with a missense MYH7 mutation (p.Cys695Arg) with an
electrocardiogram showing no clear pathological features (E). The hypertrophy can be appreciated on cardiac magnetic resonance (CMR) (A, B), but not on echo-
cardiogram (C, D).
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TABLE 3 Univariable and Multivariable Predictors of HCM Penetrance With Cox Regression
Predictor
Univariable Analysis Multivariable Analysis
HR 95% CI p Value HR 95% CI p Value
Age (10 yrs) 1.11 0.98–1.26 0.106 1.31 1.12–1.52 <0.001
Genotype
MYBPC3 1.00 – – 1.00 – –
MYH7 1.22 0.73–2.02 0.447 1.13 0.67–1.92 0.644
MYL2 0.69 0.17–2.86 0.607 0.83 0.19–3.57 0.801
TNNI3 0.22 0.08–0.62 0.004 0.19 0.07–0.55 0.002
TNNT2 0.97 0.49–1.90 0.927 0.67 0.34–1.33 0.249
TPM1 0.78 0.24–2.53 0.677 0.41 0.12–1.39 0.152
ACTC1 8.91 1.19–66.91 0.034 13.51 1.67–109.14 0.015
Multiple mutations 0.84 0.20–3.49 0.806 1.22 0.29–5.21 0.786
Male 2.03 1.32–3.14 0.001 2.91 1.82–4.65 <0.001
Abnormal ECG* 3.11 2.03–4.76 <0.001 4.02 2.51–6.44 <0.001
CMR 1.38 0.89–2.12 0.148 Analysis stratified for CMR
Hypertension 1.90 0.87–4.14 0.107 -
*At baseline or during follow-up.
CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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557not exclude a diagnosis of HCM because more than 1
in 4 patients had no major ECG abnormalities when
diagnosed with HCM.
Although the relationship between HCM and
hypertension remains to be fully clarified, because
of the young age of the study cohort, the prevalence
of hypertension in this study was low and was
not associated with increased HCM penetrance.
These findings are in line with a previous mouse
model that suggested the existence of independent
cardiac remodeling pathways in HCM and hyperten-
sion (21).
This is the first large study on disease penetrance
in SP carriers to compare echocardiography with
CMR. CMR was not clearly associated with a more
frequent diagnosis of HCM during follow-up, but a
subset of patients fulfilled diagnostic criteria on CMR
but not on echocardiography. This may be explained
by suboptimal echocardiographic imaging, particu-
larly in regions of the LV that are more challenging to
image, for example, the basal anterior and antero-
lateral wall (22). It is noteworthy that a small number
of cases who fulfilled diagnostic criteria on CMR but
not on echocardiography also had a normal ECG
(Figure 3).
The growing number of healthy SP P/LP variant
carriers is one of the greatest logistical problems
facing clinical services dedicated to the evaluation of
families with HCM, but the optimal timing and in-
terval of screening is still debated (23–25). This study
supports the need for lifelong surveillance that
should commence at a younger age than currentlyrecommended by the major societies in Europe and
North America (1,24). Our data also suggest that,
following an initial negative screening visit, the
timing of follow-up should not be tailored to age, but
rather to sex, ECG findings, and causal gene.
Although larger prospective studies are needed to
confirm our findings and establish the optimal timing
of cardiac imaging, following the documentation of P/
LP variant carrier status, CMR should be considered at
baseline in adults, adolescents, and children old
enough to undergo CMR without general anesthesia.
Although our data suggest that regular CMR scans
also should be considered during follow-up, in the
absence of a standardized protocol in this study, the
optimal interval for repeat CMR cannot be estab-
lished. Until dedicated studies become available, the
timing should, therefore, be based on the estimated
risk in the individual subject as well as cost and local
availability of CMR. Our data confirm the expected
incidence of serious complications following the
diagnosis of HCM, but also provide reassurance with
the absence of major adverse events in P/LP variant
carriers without a diagnosis of HCM, in line with
previous reports (2–8).
STUDY LIMITATIONS. This was a retrospective anal-
ysis and patients were evaluated over a long time
period in the absence of a standardized protocol. Only
half of the subjects in this study underwent CMR and
this may have led to an underestimation of dis-
ease penetrance.
Selection bias toward individuals with higher dis-
ease penetrance cannot be excluded because families
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Nearly 50% of patients with sarcomere protein gene
mutations associated with HCM who do not meet
diagnostic criteria for HCM develop HCM over 15 years
follow-up, and development of hypertrophy is more
frequent in male individuals.
TRANSLATIONAL OUTLOOK: Future studies
should address the pathophysiological mechanisms
underlying the differential hypertrophic response in
male and female carriers of sarcomere protein
mutations.
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558with multiple affected members were preferentially
offered genetic testing.
Sex is not considered in current HCM diagnostic
criteria, and this may have led to an underestimation
of penetrance in female individuals who tend to have
a lower body surface area and a lower normal LV mass
even when indexed (25). Finally, because data on
comorbidities and body mass index were not sys-
tematically collected for this study, it is impossible to
comment on their possible contribution to the
observed sex differences.
CONCLUSIONS
Following a first negative screening, approximately
50% of SP P/LP variant carriers develop HCM over
15 years of follow-up and become prone to disease
complications during long-term follow-up. Male
sex and the presence of an abnormal ECG are associ-
ated with a higher risk of disease development.
Regular CMR should be considered in long-term
screening.ADDRESS FOR CORRESPONDENCE: Dr. Perry M.
Elliott, UCL Institute for Cardiovascular Science, Paul
O’GormanBuilding, 72HuntleyStreet,LondonWC1E6DD,
UnitedKingdom.E-mail: perry.elliott@ucl.ac.uk. Twitter:
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